ClinicalTrials.gg
CompletedNCT03138655Updated Dec 21, 2020Results posted

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Phase 2 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Completed at 88 sites in 11 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
21st of 38
89 · median 110
Started
2017
with 7 others
Phase 2
5 of 38
none open now
Registered
17th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 21st largest by enrollment, is one of 8 that started in 2017, is one of 5 in phase 2, and was the 17th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD. This study will look at the PK, efficacy, immunogenicity, safety, and tolerability in participants who take vedolizumab.

The study will enroll approximately 80 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two dose regimens (high or low) per weight group >=30 kg and 10 kg to \<30 kg in ratio 1:1-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Vedolizumab high dose group - Vedolizumab 300 mg or 200 mg
  • Vedolizumab low dose group - Vedolizumab 150 mg or 100 mg

All participants will be administered vedolizumab via IV infusion. Participants assigned to the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week 14 will receive the high dose (that is, 300 mg for participants >=30 kg baseline weight and 200 mg for participants 10 kg to \<30 kg baseline weight) of vedolizumab IV at Week 14. Participants assigned to the high dose group who had not achieved clinical response continued on the same blinded high dose at Week 14.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 36 weeks. After completing the Week 22 Visit procedures, eligible participants may enter a blinded extension study. Participants will make multiple visits to the clinic, and those who do not enter extension study will have a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants who do not enter the extension study will also participate in a long-term safety follow-up, by telephone, 6 months after the last dose of study drug.

03

Conditions studied

  • Ulcerative Colitis
  • Crohn's Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants weighs >=10 kg at the time of randomization.
  2. Has a medical history of moderately to severely active UC during Screening defined as complete Mayo score of 6 to 12, and a total Mayo subscores of stool frequency and rectal bleeding >=4 and Mayo endoscopy subscore >=2, or has moderately to severely active CD defined as simple endoscopic score for Crohn's disease (SES-CD) >=7, and the CDAI components of average daily abdominal pain score of greater than (>) 1 for the 7 days prior, and total number of liquid/very soft stools >10 within 7 days prior to first dose of study drug.
  3. Has evidence of UC extending proximal to the rectum (that is, not limited to proctitis) or evidence of CD involving the ileum and/or colon, at a minimum.
  4. Has extensive colitis or pancolitis of >8 years duration or left-sided colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to their first dose of study drug.
  5. Has a family history of colorectal cancer (that is, first-degree relative), personal history of increased colorectal cancer risk, or other known risk factor must be up-to-date on colorectal cancer surveillance.
  6. The participant's vaccinations are up to date.
  7. Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:

    :

    • Signs and/or symptoms of persistently active disease despite a history of at least one 4-week induction regimen that included a dose equivalent to or more than prednisone 1 milligram per kilogram (mg/kg) daily orally for 2 weeks or IV for 1 week.

    OR

    • Two failed attempts to taper corticosteroids to below a dose equivalent to prednisone 10 mg daily orally on 2 separate occasions.

    OR

    • History of significant intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).

    Immunomodulators:

    • Signs and symptoms of persistently active disease despite a history of at least one 8-week regimen of oral azathioprine (AZA) (>=1.5 milligram per kilogram per day [mg/kg/day]) or 6-mercaptopurine (6-MP) mg/kg (>=1.0 mg/kg/day) or methotrexate (MTX) (>=10 milligram per square meter [mg/m\^2] once a week).

    OR

    • History of intolerance of at least 1 immunomodulator (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, liver function test (LFT) abnormalities, lymphopenia, thiopurine methyltransferase genetic mutation, infection).

    Tumor necrosis factor-alpha (TNF-α) antagonists:

    • Signs and symptoms of persistently active disease despite a history of at least 1 induction regimen of infliximab 5 mg/kg IV at Week 0 and Weeks 2 and 6 or adalimumab 2-week regimen of 160 mg on Day 1 and 80 mg on Day 15 if >=40 kg or 80 mg on Day 1 and 40 mg on Day 15 if \<40 kg. For any other TNF-α antagonist, the participant must demonstrate signs and symptoms of persistently active disease despite a history of at least 1 induction regimen, as determined by the investigator.

    OR

    • Recurrence of symptoms during maintenance dosing following prior clinical benefit, that is, fitting clinically with secondary loss of response (discontinuation despite clinical benefit does not qualify).

    OR

    • History of intolerance of infliximab or adalimumab (including, but not limited to, infusion-related reaction, demyelination, congestive heart failure, infection).
  8. The participant may be receiving a therapeutic dose of the following drugs:

    1. Oral 5-aminosalicylic acid (5-ASA) compounds, providing the dose has been stable for the 2 weeks prior to first dose of study drug.
    2. Oral corticosteroid therapy (prednisolone at a stable dose \<=50 mg/day, or equivalent steroid), provided that the dose has been stable for the 4 weeks prior to first dose of study drug if corticosteroids have been initiated, or for the 2 weeks prior to first dose of study drug if corticosteroids are being tapered.
    3. Probiotics (example, Saccharomyces boulardii), provided the dose has been stable for the 2 weeks prior to first dose of study drug.
    4. Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
    5. Antibiotics used for the treatment of CD (example, ciprofloxacin, metronidazole), providing the dose has been stable for the 2 weeks prior to first dose of study drug.
    6. Azathioprine or 6-MP, provided the dose has been stable for the 8 weeks prior to first dose of study drug.
    7. Methotrexate (MTX), provided the dose has been stable for the 8 weeks prior to first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has had previous exposure to approved or anti-integrins (example, natalizumab, efalizumab, etrolizumab, or AMG 181) or MAdCAM-1 antagonists, or rituximab.
  2. Has had prior exposure to vedolizumab.
  3. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist prior to the administration of the first dose of study drug.
  4. Requires surgical intervention for UC or CD, or is anticipated to require surgical intervention for UC or CD during this study.
  5. Use of topical (rectal) treatment with 5-ASA or enemas/suppositories within 2 weeks of the administration of the first dose of study drug.
  6. Has any unstable or uncontrolled cardiovascular, heart failure moderate to severe (New York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  7. Active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of Screening or during the Screening Period that is positive, defined as:

    • Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR
    • A TB skin test reaction >=5 millimeter (mm). Participants with documented previously treated TB with a negative QuantiFERON test can be included in the study.
  8. current or recent history (within 1 year prior to enrollment) of alcohol dependence or illicit drug use.
  9. Has a current diagnosis of indeterminate colitis (Inflammatory bowel disease unclassified [IBDU]). For participants less than 6 years of age, any findings that suggest monogenic very early onset inflammatory bowel disease should be excluded.
  10. Has evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.
  11. Has ileostomy, colostomy, ileo-anal pouch, or known fixed symptomatic stenosis of the intestine.
  12. Has extensive colonic resection, example, subtotal or total colectomy.
  13. Has a history or evidence of adenomatous colonic polyps that have not been removed.
  14. Has a history or evidence of colonic mucosal dysplasia.
  15. Has chronic virus (HBV) infection* or chronic virus (HCV) infection. * HBV immune participants (that is, being hepatitis B surface antigen [HBsAg] negative and hepatitis B antibody positive) may be included, however.
  16. Has any identified congenital or acquired immunodeficiency (example, common variable immunodeficiency, [HIV] infection, organ transplantation).
  17. Has evidence of or treatment for Clostridium difficile (C difficile) infection within 60 days or other intestinal pathogen within 30 days prior to first dose of study drug.
  18. Has any history of , except for the following: (a) adequately treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to enrollment; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to first dose of study drug. Participants with remote history of malignancy (example, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received, and inclusion must be discussed with the sponsor on a case-by-case basis prior to enrollment.
  19. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  20. Has history of lupus.
  21. Has had a surgical procedure requiring general anesthesia within 30 days prior to screening or is planning to undergo major surgery during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    UC: <30 kg Participants, Vedolizumab 100 mg

    Participants with UC having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    UC: <30 kg Participants, Vedolizumab 200 mg

    Participants with UC having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    CD: <30 kg Participants, Vedolizumab 100 mg

    Participants with CD having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    CD: <30 kg Participants, Vedolizumab 200 mg

    Participants with CD having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    UC: >=30 kg Participants, Vedolizumab 150 mg

    Participants with UC having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    UC: >=30 kg Participants, Vedolizumab 300 mg

    Participants with UC having baseline weight of \>=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    CD: >=30 kg Participants, Vedolizumab 150 mg

    Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

  • Experimental
    CD: >=30 kg Participants, Vedolizumab 300 mg

    Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion.

    Also known as: MLN0002, ENTYVIO, KYNTELES

06

What researchers measure

Primary outcomes

  1. AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14

    Time frame: From Day 43 (Week 6) post-dose up to pre-dose Day 99 (Week 14)

  2. Cav,Week 14: Average Serum Concentration During a Dosing Interval at Week 14

    Time frame: From Day 43 (week 6) post-dose up to pre-dose Day 99 (Week 14)

  3. Ctrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 14

    Time frame: At the end of a dosing interval at Week 14

Secondary outcomes

  1. Percentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score

    Clinical response was defined as a reduction in complete Mayo score of \>= 3 points and \>=30 % from Baseline with an accompanying decrease in rectal bleeding sub-score of \>=1 point(s) or absolute rectal bleeding sub-score of \<= 1 point. Mayo score was used in to assess UC disease activity. It consisted of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale was scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo score ranged from 0 to 12, with higher scores indicating more severe disease.

    Time frame: Baseline (Day 1) and Week 14

  2. Percentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI)

    Clinical response was defined as \>=70 points decrease from Baseline in CDAI score at Week 14. The CDAI evaluated severity of signs and symptoms of CD. Information was collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that were combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below were associated with quiescent disease; values above that indicated active disease, values \>=220 indicated moderate to severe disease, and values above 450 were seen with extremely severe disease.

    Time frame: Baseline (Day 1) and Week 14

07

Results

Posted Dec 21, 2020

Participant flow

Participants took part in the study at 72 investigative sites in United States, Belgium, Canada, France, Germany, Hungary, Israel, Netherlands, Poland, Ukraine, United Kingdom and European Union from 8 November 2017 to 26 March 2020.

Participant flow — Overall Study
MilestoneUC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mg
Started109111013121212
Completed7797117910
Not completed32232532
Withdrew: Adverse event21211422
Withdrew: Withdrawal by subject01000010
Withdrew: Reason not specified10021100

Outcome measures

PrimaryAUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14
Time frame:
From Day 43 (Week 6) post-dose up to pre-dose Day 99 (Week 14)
Reported as:
Mean · h*ng/mL
AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14
h*ng/mLUC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mg
AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 141933.5076 ± 1184.362843231.1001 ± 1152.066282344.4204 ± 1216.583453091.7957 ± 1732.347952449.9433 ± 772.666774182.4869 ± 1751.879401865.0004 ± 509.682683176.6971 ± 928.32630
PrimaryCav,Week 14: Average Serum Concentration During a Dosing Interval at Week 14
Time frame:
From Day 43 (week 6) post-dose up to pre-dose Day 99 (Week 14)
Reported as:
Mean · ng/mL
Cav,Week 14: Average Serum Concentration During a Dosing Interval at Week 14
ng/mLUC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mg
Cav,Week 14: Average Serum Concentration During a Dosing Interval at Week 1439.3143 ± 21.3409761.2934 ± 18.1444646.8716 ± 23.0733463.6275 ± 28.2911644.6465 ± 11.4850077.2452 ± 28.4951137.4752 ± 18.2652863.1734 ± 15.08119
PrimaryCtrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 14
Time frame:
At the end of a dosing interval at Week 14
Reported as:
Mean · ng/mL
Ctrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 14
ng/mLUC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mg
Ctrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 149.3100 ± 9.4804510.7226 ± 10.354238.7395 ± 7.7738610.3685 ± 11.3012416.3645 ± 16.9386921.4860 ± 18.018723.9006 ± 3.629917.8310 ± 9.44044
SecondaryPercentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score

Clinical response was defined as a reduction in complete Mayo score of \>= 3 points and \>=30 % from Baseline with an accompanying decrease in rectal bleeding sub-score of \>=1 point(s) or absolute rectal bleeding sub-score of \<= 1 point. Mayo score was used in to assess UC disease activity. It consisted of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale was scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo score ranged from 0 to 12, with higher scores indicating more severe disease.

Time frame:
Baseline (Day 1) and Week 14
Reported as:
Number · percentage of participants
Percentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score
percentage of participantsUC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mg
Percentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score40.0 (12.2 to 73.8)66.7 (29.9 to 92.5)69.2 (38.6 to 90.9)41.7 (15.2 to 72.3)
SecondaryPercentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI)

Clinical response was defined as \>=70 points decrease from Baseline in CDAI score at Week 14. The CDAI evaluated severity of signs and symptoms of CD. Information was collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that were combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below were associated with quiescent disease; values above that indicated active disease, values \>=220 indicated moderate to severe disease, and values above 450 were seen with extremely severe disease.

Time frame:
Baseline (Day 1) and Week 14
Reported as:
Number · percentage of participants
Percentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI)
percentage of participantsCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mg
Percentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI)63.6 (30.8 to 89.1)40.0 (12.2 to 73.8)45.5 (16.7 to 76.6)33.3 (9.9 to 65.1)

Adverse events

Collected over From first dose of study drug up to Week 32. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
<30 kg Participants, Vedolizumab 100 mg0/17 (0%)4/17 (23.5%)16/17 (94.1%)
<30 kg Participants, Vedolizumab 200 mg0/19 (0%)6/19 (31.6%)13/19 (68.4%)
<30 kg Participants, Vedolizumab 100 mg to 200 mg0/4 (0%)2/4 (50%)3/4 (75%)
>=30 kg Participants, Vedolizumab 150 mg0/18 (0%)2/18 (11.1%)15/18 (83.3%)
>=30 kg Participants, Vedolizumab 300 mg0/24 (0%)8/24 (33.3%)20/24 (83.3%)
>=30 kg Participants, Vedolizumab 150 mg to 300 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
Event<30 kg Participants, Vedolizumab 100 mg<30 kg Participants, Vedolizumab 200 mg<30 kg Participants, Vedolizumab 100 mg to 200 mg>=30 kg Participants, Vedolizumab 150 mg>=30 kg Participants, Vedolizumab 300 mg>=30 kg Participants, Vedolizumab 150 mg to 300 mg
AnaemiaBlood and lymphatic system disorders0/171/191/40/181/240/6
Abdominal painGastrointestinal disorders0/171/191/40/180/240/6
ColitisGastrointestinal disorders0/170/191/40/180/240/6
Decreased appetiteMetabolism and nutrition disorders0/170/191/40/180/240/6
Viral infectionInfections and infestations0/170/190/40/180/241/6
Crohn's diseaseGastrointestinal disorders0/173/190/41/182/240/6
Colitis ulcerativeGastrointestinal disorders0/172/190/41/183/240/6
Clostridium difficile infectionInfections and infestations1/170/190/40/180/240/6
Pelvic abscessInfections and infestations1/170/190/40/180/240/6
VaricellaInfections and infestations1/170/190/40/180/240/6
Most frequent other events
Showing 10 of 137
Most frequent other events
Event<30 kg Participants, Vedolizumab 100 mg<30 kg Participants, Vedolizumab 200 mg<30 kg Participants, Vedolizumab 100 mg to 200 mg>=30 kg Participants, Vedolizumab 150 mg>=30 kg Participants, Vedolizumab 300 mg>=30 kg Participants, Vedolizumab 150 mg to 300 mg
VomitingGastrointestinal disorders1/171/192/41/180/240/6
DiarrhoeaGastrointestinal disorders0/170/192/40/181/240/6
NauseaGastrointestinal disorders1/170/190/40/180/242/6
HeadacheNervous system disorders1/172/190/42/183/242/6
DizzinessNervous system disorders1/170/190/40/180/242/6
CoughRespiratory, thoracic and mediastinal disorders0/172/190/40/181/242/6
Abdominal painGastrointestinal disorders5/173/191/40/181/240/6
Abdominal distensionGastrointestinal disorders0/171/191/41/180/240/6
Abnormal faecesGastrointestinal disorders0/170/191/40/180/240/6
Anal fissureGastrointestinal disorders0/170/191/40/180/240/6

Baseline characteristics

Randomized Set included all participants who are randomized into the study regardless whether they received any dose of study drug or not.

Age, Continuous
Age, Continuous(years)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Mean7.0 (3 to 12)8.0 (2 to 12)7.4 (2 to 12)8.1 (3 to 12)12.4 (8 to 17)13.9 (9 to 17)13.4 (10 to 17)14.3 (11 to 17)10.56 (2 to 17)
Sex: Female, Male
Sex: Female, Male(Participants)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Female4445568339
Male6575864950
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Hispanic or Latino022211109
Not Hispanic or Latino107781211111278
Unknown or Not Reported002000002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
American Indian or Alaska Native000000000
Asian000000112
Native Hawaiian or Other Pacific Islander000000000
Black or African American121020208
White7779111091171
More than one race001002003
Unknown or Not Reported202100005
Region of Enrollment
Region of Enrollment(Participants)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Belgium100001215
France001000001
Hungary1011344317
Poland2142102315
United Kingdom001110126
Ukraine110000002
Israel3202320113
Canada000000101
United States2544552229
Height
Height(cm)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Mean119.59 (82.7 to 146.0)122.39 (84.9 to 143.0)120.58 (83.5 to 146.0)124.67 (96.5 to 137.6)153.11 (128.0 to 176.1)160.03 (138.3 to 185.4)157.85 (134.3 to 182.5)157.98 (141.9 to 181.5)139.53 (82.7 to 185.4)
Weight
Weight(kg)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Mean22.38 (12.8 to 29.6)23.23 (10.2 to 29.8)22.06 (12.0 to 29.9)23.37 (14.3 to 30.0)46.22 (30.3 to 75.9)53.98 (32.0 to 78.9)51.53 (31.4 to 79.0)45.89 (33.9 to 68.0)36.08 (10.2 to 79.0)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)UC: <30 kg Participants, Vedolizumab 100 mgUC: <30 kg Participants, Vedolizumab 200 mgCD: <30 kg Participants, Vedolizumab 100 mgCD: <30 kg Participants, Vedolizumab 200 mgUC: >=30 kg Participants, Vedolizumab 150 mgUC: >=30 kg Participants, Vedolizumab 300 mgCD: >=30 kg Participants, Vedolizumab 150 mgCD: >=30 kg Participants, Vedolizumab 300 mgTotal
Mean15.63 (13.4 to 18.7)15.29 (12.4 to 20.0)15.04 (13.5 to 17.2)14.93 (12.4 to 16.9)19.51 (16.4 to 26.5)20.76 (16.7 to 27.1)20.50 (14.4 to 24.5)18.26 (15.8 to 25.9)17.49 (12.4 to 27.1)
08

Study locations

88 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California San Francisco
    San Francisco, California 94143-0135, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106-3322, United States
  • Nemours Children's Clinic
    Wilmington, Delaware 19803, United States
  • Nemours Childrens Specialty Care - Jacksonville
    Jacksonville, Florida 32207, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Children's Center for Digestive Healthcare
    Atlanta, Georgia 30342, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60614, United States
  • Indiana University School of Medicine - Indianapolis
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905-0001, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • The Children's Hospital at Montefiore
    Bronx, New York 10467, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10031, United States
  • University Hospitals Rainbow Babies & Children's Hospital
    Cleveland, Ohio 44106, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Childrens Medical Center of Dallas
    Dallas, Texas 75235, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Children's Specialty Group - Medical Center Location
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Universitair Ziekenhuis Brussel
    Brussel, Brussels 1090, Belgium
  • Hopital Universitaire des Enfants Reine Fabiola
    Bruxelles, Brussels 1020, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • University of Alberta
    Edmonton, Alberta T6G 1C9, Canada
  • Children's and Women's Health Centre of British Columbia
    Vancouver, British Columbia V6H 3V4, Canada
  • Children's Hospital of Winnipeg
    Winnipeg, Manitoba R3A 1S1, Canada
  • IWK Health Centre
    Halifax, Nova Scotia B3K 6R8, Canada
  • McMaster Children's Hospital
    Hamilton, Ontario L8N 3Z5, Canada
  • London Health Sciences Centre University Hospital
    London, Ontario N6A 5W9, Canada
  • Toronto Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Centre Hospitalier Universitaire Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
  • McGill University Health Centre Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Hopital Necker-Enfants Malades
    Paris Cedex 15, Ile-de-france 75015, France
  • Hopital Robert Debre
    Paris Cedex 19, Ile-de-france 75935, France
  • Hopital Jeanne de Flandre
    Lille, NORD Pas-de-calais 59037, France
  • Hopital de la Timone
    Marseille Cedex 5, Provence Alpes COTE D'azur 13385, France
  • Universitatsklinikum Ulm
    Ulm, Baden-wuerttemberg 89075, Germany
  • Ludwig-Maximillians-Universitat Munchen
    Munchen, Bayern 80337, Germany
  • Universitatsmedizin Rostock - Kinder und Jugendklinik
    Rostock, Mecklenburg-vorpommern 18057, Germany
  • Universitatsklinikum Aachen
    Aachen, Nordrhein-westfalen 52074, Germany
  • Universitaetsklinikum Leipzig AoeR
    Leipzig, Sachsen 04103, Germany
  • BAZ Megyei Korhaz es Egyetemi Oktatokorhaz
    Miskolc, Borsod-abauj-zemplen 3526, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrad 6720, Hungary
  • Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet
    Sopron, Gyor-moson-sopron 9400, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdu-bihar 4032, Hungary
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Soroka University Medical Center
    Beer-sheva, Beersheba 8410101, Israel
  • Schneider Children's Medical Center of Israel
    Petach Tikvah, Petah Tiqwa 4920235, Israel
  • Assaf Harofeh Medical Center
    Zerifin, Rehoboth 7030000, Israel
  • The Edmond and Lily Safra Children's Hospital - Sheba Medical Center
    Ramat Gan, Tel Aviv 52621, Israel
  • Rambam Health Care Campus - Rambam Medical Center
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Radboud Universitair Medisch Centrum
    Nijmegen, GA 6525, Netherlands
  • Emma Kinderziekenhuis AMC
    Amsterdam, Noord-holland 1105AZ, Netherlands
  • Isala Klinieken
    Zwolle, Overijssel 8025 AB, Netherlands
  • Erasmus University Medical Center
    Rotterdam, Zuid-holland 3015 GJ, Netherlands
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, Dolnoslaskie 50-369, Poland
  • Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi Osrodek Pediatryczny im Marii Konopnic
    Lodz, Lodzkie 91-738, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, Lodzkie 93-338, Poland
  • Uniwersytecki Szpital Dzieciecy w Krakowie
    Krakow, Malopolskie 30-663, Poland
  • Warszawski Uniwersytet Medyczny
    Warsaw, Mazowieckie 01-184, Poland
  • Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski
    Rzeszow, Podkarpackie 35-302, Poland
  • Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa w Bialymstoku
    Bialystok, Podlaskie 15-274, Poland
  • Copernicus Podmiot Leczniczy
    Gdansk, Pomorskie 80-803, Poland
  • Samodzielny Publiczny Specjalistyczny Zaklad Opieki Zdrowotnej ZDROJE
    Szczecin, Zachodniopomorskie 70-780, Poland
  • National Scientific Center of Radiological Medicine of NAMS of Ukraine
    Kyiv, Kiev City 03115, Ukraine
  • Kharkiv Regional Clinical Children's Hospital
    Kharkiv, 61093, Ukraine
  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, England B4 6NH, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, England CB2 0QQ, United Kingdom
  • Barts and The London NHS Trust
    London, England E1 1BB, United Kingdom
  • King's College Hospital
    London, England SE5 9RS, United Kingdom
  • Great Ormond Street Hospital for Children NHS Trust
    London, England WC1N 3JH, United Kingdom
  • Central Manchester University Hospitals NHS Foundation Trust
    Manchester, England M13 9WL, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, England NG7 2UH, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, England OX3 9DU, United Kingdom
  • Sheffield Children's NHS Foundation Trust
    Sheffield, England S10 2TH, United Kingdom
  • NHS Greater Glasgow and Clyde
    Glasgow, Scotland G51 4TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2020, 28 months.

Results were first posted in Dec 2020, 8 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 28 months is close to that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2017
First posted
May 3, 2017
StartActual
Nov 8, 2017
Primary completionActual
Mar 31, 2020
CompletionActual
May 26, 2020
Results first posted
Dec 21, 2020
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03138655
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Nov 8, 2017
Primary completion
Mar 31, 2020
Completion
May 26, 2020
Results posted
Dec 21, 2020
Last update
Dec 21, 2020

Study contacts

Medical Monitor Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion